NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCTs032230674

Registered date:05/03/2024

Feasibility study of a smartphone application in type 2 diabetes with stage 2 diabetic nephropathy

Basic Information

Recruitment status Recruiting
Health condition(s) or Problem(s) studiedType 2 diabetes mellitus with stage 2 diabetic nephropathy
Date of first enrollment05/03/2024
Target sample size15
Countries of recruitment
Study typeInterventional
Intervention(s)A newly developed smartphone application-based treatment program will be used for type 2 diabetes patients with stage 2 diabetic nephropathy.

Outcome(s)

Primary OutcomeTwo-sample test for change in HbA1c before and after treatment
Secondary OutcomeTwo-sample test will be conducted on the amount of change in the following items before and after treatment. Physical examination: blood pressure, BMI Blood and urine tests: LDL cholesterol, HDL cholesterol, triglycerides, creatinine, urinary albumin, eGFRQuestionnaire: ADDQoL, DTSQs and DTSQc will be compared Descriptive statistics on the following items during the treatment period Number of times the application is opened and recorded concerning weight, blood pressure, diet, other lifestyle habits

Key inclusion & exclusion criteria

Age minimum>= 18age old
Age maximum<= 80age old
GenderBoth
Include criteria1. patients with type 2 diabetes 2. patients who use smartphones on a daily basis and are able to use the smartphone application included in this program to enter lifestyle-related data and take educational content. 3. patients with a recent urinary albumin level of 30 mg/g Cr or more and less than 300 mg/g Cr, or a urine albumin level of 30 mg/day or more and less than 300 mg/day within the first half year before consent is obtained 4. patients with an eGFR of 30 mL/min/1.73 m2 or greater within 6 months prior to obtaining consent 5. patients whose daily food intake (excluding snacks) is 3 times a day 6. patients who are at least 18 years old and less than 80 years old at the time of obtaining consent 7. patients with a recent HbA1c of 7% or more but less than 10% within the last year prior to obtaining consent
Exclude criteria1. patients with BMI less than 15 kg/m2 2. patients with cancer (malignant tumor (equivalent to C00-C97 in ICD-10 classification) that has not been cured within 5 years, or intraepithelial neoplasia (equivalent to D00-D09 in ICD-10 classification) that has not been cured within 1 year) 3. patients with hepatic impairment of Child-Pugh B or higher 4. pregnant or lactating patients 5. patients who are unable to enter lifestyle-related data into the smartphone application by themselves and require a proxy to do so 6. other patients whom the physician deems inappropriate

Related Information

Contact

Public contact
Name Kitazawa Masaru
Address 754 Asahimachi-dori Ichibancho, Chuo-ku, Niigat a City, Niigata Prefecture Niigata Japan 951-8520
Telephone +81-25-368-9026
E-mail m-kitazawa@med.niigata-u.ac.jp
Affiliation Niigata University Medical and Dental Hospital
Scientific contact
Name Sone Hirohito
Address 754 Asahimachi-dori Ichibancho, Chuo-ku, Niigat a City, Niigata Prefecture Niigata Japan 951-8520
Telephone +81-25-368-9026
E-mail sone@med.niigata-u.ac.jp
Affiliation Niigata University Medical and Dental Hospital